but it still has a strong presence in the Middle East and North Africa (MENA) region. The fund is intended to aid Hikma Pharmaceuticals' efforts in the digital health sector whilst supplementing ...

The introduction of the Shield™ test for colorectal cancer screening marks a transformative step in advancing precision and ...

London – M42, a global health leader powered by artificial intelligence (AI), and Hikma Pharmaceuticals PLC (Hikma), ...

Hikma Pharmaceuticals PLC hit a new 52-week high, surpassing its previous peak of £23.14, which the company achieved on ...

Darwazah has been with Hikma Pharmaceuticals for 42 years. He has been the CEO since 2007 and was appointed executive chairman in 2014. The company is listed on the London Stock Exchange and is the ...

For example, the Hikma Pharmaceuticals PLC (LON:HIK) share price is up 23% in the last 5 years, clearly besting the market return of around 3.1% (ignoring dividends). However, more recent returns ...

PLC (LSE: HIK), a global pharmaceutical company, is set to announce its financial results for the year ending December 31, 2024, on Wednesday, February 26, 2025. The company will make a recording of ...

Hikma Pharmaceuticals PLC HIK shares rose 1.79% to £19.88 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.22% to ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the ...